Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SNGX | US
-0.28
-7.12%
Healthcare
Biotechnology
30/06/2024
21/10/2024
3.59
3.80
3.90
3.50
Soligenix Inc. a late-stage biopharmaceutical company focuses on developing and commercializing products to treat rare diseases in the United States. The company operates in two segments Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte) a novel photodynamic therapy which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942 an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 1721-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax a ricin toxin vaccine candidate which has completed Phase Ia and Ib clinical trials; SGX943 a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax a technology in pre-clinical development for thermostabilizing vaccines; and CiVax a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma Inc. and changed its name to Soligenix Inc. in 2009. Soligenix Inc. was incorporated in 1987 and is headquartered in Princeton New Jersey.
View LessValue Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
88.9%1 month
146.0%3 months
137.0%6 months
2172.2%-
-
2.39
0.84
0.30
-0.12
1.87
-1.52
-7.77M
8.19M
8.19M
-
-74.50K
-
-98.90
-152.02
1.42
5.61
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.95
Range1M
1.37
Range3M
3.22
Rel. volume
0.75
Price X volume
608.30K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Arsanis Inc | ASNS | Biotechnology | 1.38 | 8.30M | -4.83% | n/a | 252.35% |
Plus Therapeutics Inc | PSTV | Biotechnology | 1.4 | 8.25M | -2.78% | n/a | -45.04% |
TFFP | TFFP | Biotechnology | 2.3 | 7.97M | 11.11% | n/a | 1.26% |
Alzamend Neuro Inc. Common Stock | ALZN | Biotechnology | 1.73 | 7.74M | 3.28% | n/a | 0.00% |
Moleculin Biotech Inc | MBRX | Biotechnology | 2.67 | 7.59M | 3.29% | n/a | 3.00% |
Pulmatrix Inc | PULM | Biotechnology | 2.04 | 7.45M | 0.97% | n/a | 0.18% |
Cyclerion Therapeutics Inc | CYCN | Biotechnology | 2.9099 | 7.32M | 16.40% | n/a | 0.00% |
Orgenesis Inc | ORGS | Biotechnology | 1.53 | 7.30M | -27.49% | n/a | -84.02% |
Virax Biolabs Group Limited Ordinary Shares | VRAX | Biotechnology | 1.63 | 7.08M | 6.54% | n/a | 4.18% |
Purple Biotech Ltd | PPBT | Biotechnology | 4.49 | 7.07M | 2.75% | n/a | 0.89% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.12 | 0.53 | Cheaper |
Ent. to Revenue | 1.87 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 2.39 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 137.03 | 72.80 | Riskier |
Debt to Equity | 0.84 | -1.23 | Expensive |
Debt to Assets | 0.30 | 0.25 | Par |
Market Cap | 8.19M | 3.66B | Emerging |